AIRWAY THERAPEUTICS

Created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia in newborns.

WHAT IS BPD?

Bronchopulmonary dysplasia is a developmental disorder in premature neonates that leads to an arrested lung development, which in turn results in chronic lung disease. Today, current therapies lack critical proteins necessary to prevent the onset of BPD.

AT-100

AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, absent from current therapies, is a normal protein component of lung surfactant that performs three critical roles in maintaining healthy lung function.